LBA 18: Improvement in Survival with the Addition of Talazoparib to First-Line Enzalutamide Treatment in RR-Deficient mCRPC Patients
The TALAPRO-2 study showed a significant improvement in overall survival in men with mCRPC treated with the combination of talazoparib and enzalutamide, regardless of whether they had HRR gene alterations. In this sub-analysis, men without HRR-deficient cancers or with unknown HRR status had a modest clinical benefit.
Få tilgang
Hvis du er lege, sykepleier eller annen helsepersonell, kan du få tilgang til hele artikkelen ved å opprette en profil på BestPractice Nordic.
- Få tilgang
- Hvis du allerede har en profil: Logg in
